Nitrozumab injection is a targeted drug for patients with stage III and IV nasopharyngeal carcinoma with positive expression of epidermal growth factor receptor (EGFR), which can specifically target tumor cells. Nitrozumab injection for nasopharyngeal carcinoma is often combined with chemotherapy in clinical practice to improve the therapeutic effect. Patients who are older and in poor general condition can also be treated with nitrozumab injection alone. The medication should be administered under the guidance of experienced doctors, and the medication should be administered intravenously. During the medication period, the patient’s vital signs should be closely monitored, and symptoms such as blood pressure drop, dizziness, nausea and vomiting may occur after the medication. Nitrozumab injection can cross the placental barrier, and studies suggest that EGFR is related to fetal tissue differentiation and organ formation, so it should be used with caution in pregnant women or women who do not take effective contraceptive measures.